MoonLake Immunotherapeutics (NASDAQ: MLTX) CSO entity sells 16,105 shares
Rhea-AI Filing Summary
MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported an indirect sale by JeruCON Beratungsgesellschaft mbH of 16,105 Class A shares on July 15, 2026 under a Rule 10b5-1 trading plan adopted March 10, 2026 at a weighted average price of $20.01 per share, with individual trades from $20.00 to $20.04.
After the sale, JeruCON remained the indirect holder of 2,808,446 Class A ordinary shares, while Reich directly held 35,389 Class A shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 16,105 shares
Net Sell
2 txns
Insider
Reich Kristian
Role
Chief Scientific Officer
Sold
16,105 shs ($322K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A ordinary shares, par value $0.0001 per share F1, F2, F3 | 16,105 | $20.01 | $322K |
| holding | Class A ordinary shares, par value $0.0001 per share | -- | -- | -- |
Holdings After Transaction:
Class A ordinary shares, par value $0.0001 per share — 2,808,446 shares (Indirect, See footnote.);
Class A ordinary shares, par value $0.0001 per share — 35,389 shares (Direct)
Footnotes (3)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
- F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
Key Figures
Shares sold: 16,105 shares
Weighted average sale price: $20.01 per share
Indirect holdings after sale: 2,808,446 shares
+2 more
5 metrics
Shares sold
16,105 shares
Class A ordinary shares sold on July 15, 2026 by JeruCON Beratungsgesellschaft mbH
Weighted average sale price
$20.01 per share
Weighted average price, with trades from $20.00 to $20.04
Indirect holdings after sale
2,808,446 shares
Class A ordinary shares indirectly owned through JeruCON after the July 15, 2026 sale
Direct holdings
35,389 shares
Class A ordinary shares held directly by Kristian Reich as of July 15, 2026
Rule 10b5-1 plan adoption date
March 10, 2026
Date the trading plan governing the reported sale was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, indirect beneficial owner, Section 16
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported represents the weighted average sale price per share for the multiple transactions."
indirect beneficial owner regulatory
"may be deemed to be the indirect beneficial owner of the ordinary shares owned by JeruCON."
Section 16 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Was the MoonLake (MLTX) insider sale under a Rule 10b5-1 trading plan?
Yes. A footnote explains that the July 15, 2026 sale of 16,105 MoonLake Class A shares was executed under a Rule 10b5-1 trading plan adopted on March 10, 2026, indicating the trades were pre-arranged rather than discretionary.
Does Kristian Reich’s latest MoonLake (MLTX) Form 4 report any derivative securities?
No. Only one non-derivative transaction is shown: a sale of 16,105 Class A ordinary shares associated with JeruCON. No options, warrants, or other derivative securities are included in the reported transactions.